David Heredia Highlighted New Research on Membrane Targets in RET+ NSCLC
David Heredia, Head of the Oncology Department at Punta Médica, shared a post on X by Arianna Marinello at al., published in JAMA Network:
“In RET+ NSCLC, multiple membrane targets beyond RET may guide future therapy:
- PD-L1, HER2, EGFR, TROP2 commonly expressed
- MET, NTRK, CLDN18.2 in smaller subsets
Combos: RET TKIs + IO or antibody–drug conjugates
Future research should further explore these membrane proteins in dedicated clinical trials, with a priority for agents targeting MET expression.”
Title: Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer
Journal: JAMA Network
Authors: Arianna Marinello, Maria Rosa Ghigna, Julia K. Rotow, Tolulope Adeyelu, Giulio Metro, Mariana Brandão, Florian Guisier, Isabelle Monnet, Hortense Gaultier de Saint Basile, Carlo Genova, Judith Raimbourg, Safae Terrisse, Karine Godefroy, Luca Toschi, Martina Mandarano, Hélène Doubre, Alessandro Russo, Alexander Valent, Abdul Rafeh Naqash, Ayesha Aijaz, Anas Gazzah, Jordi Remon, Ari Vanderwalde, Andrew Elliott, Balazs Halmos, Fabrice Barlesi, David Planchard, Pasi A. Jänne, Benjamin Besse, Mihaela Aldea
More posts featuring David Heredia on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023